US 2011 0014248A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0014248 A1 Castiel et al. (43) Pub. Date: Jan. 20, 2011

(54) COSMETIC USE OF MICROORGANISM(S) Publication Classification FOR THE TREATMENT OF SCALP (51) Int. Cl. DSORDERS A6IR 8/02 (2006.01) 46R 8/99 (2006.01) (75) Inventors: Isabelle Castiel, Nice (FR): A6II 35/74 (2006.01) Audrey Gueniche, Rueil A69/68 (2006.01) Malmaison (FR) A6IR 9/00 (2006.01) A69/48 (2006.01) Correspondence Address: A6IR 9/28 (2006.01) OBLON, SPIVAK, MCCLELLAND MAIER & A6IP 7/4 (2006.01) NEUSTADT, L.L.P. A61O 5/02 (2006.01) 194O DUKE STREET A61O 5/06 (2006.01) ALEXANDRIA, VA 22314 (US) A61O 5/10 (2006.01) A61O 5/12 (2006.01) (73) Assignees: LOREAL, Paris (FR); NESTEC A61O II/00 (2006.01) SA, Vevey (CH) (52) U.S. Cl...... 424/401; 424/93.45; 424/93.4: 424/93.3; 424/93.44; 424/93.51; 424/93.46; (21) Appl. No.: 12/659,597 424/48; 424/439: 424/484; 424/456; 424/474; (22) Filed: Mar. 15, 2010 424/50: 424/70.1; 424/70.6 (57) ABSTRACT Related U.S. Application Data The present invention relates to a use of an effective amount (63) Continuation of application No. 12/509,756, filed on of at least one probiotic microorganism and/or a fraction Jul. 27, 2009, now abandoned. thereof and/or a metabolite thereof for preventing and/or treating dandruff disorders of the scalp, as well as a cosmetic (60) Provisional application No. 61/084,582, filed on Jul. process for preventing and/or treating a dandruff condition 29, 2008, provisional application No. 61/213,517, including the administration a first cosmetic active agent and filed on Jun. 16, 2009. of at least a second cosmetic active agent, topically, the said first and second cosmetic active agents being formulated in (30) Foreign Application Priority Data separate compositions, the first cosmetic active agent being chosen from probiotic microorganisms, and mixtures thereof, Nov. 19, 2008 (FR) ...... 08 57865 and the second cosmetic active agent being chosen from Jun. 2, 2009 (FR) ...... O953611 antidandruff active agents. Patent Application Publication Jan. 20, 2011 Sheet 1 of 4 US 2011/0014248A1

Rando 12 IA IB

D1 D15 D29 D43 D57 D64 TIME Fig. 1 Patent Application Publication Jan. 20, 2011 Sheet 2 of 4 US 2011/0014248 A1

Rando I A 12 b IB

D1 D15 D29 D43 D57 D64 TIME Fig.2 Patent Application Publication Jan. 20, 2011 Sheet 3 of 4 US 2011/0014248 A1

Rando IA 8 IB

6

4.

D1 D15 D29 D43 D5, D64 TIME Fig. 3 Patent Application Publication Jan. 20, 2011 Sheet 4 of 4 US 2011/0014248 A1

Rando IA 1,80 I B S 1.50 : 120 s 0.90 0.60

0.30 D1 D15 D29 D43 D57 D64 TIME Fig. 4 US 2011/0014248 A1 Jan. 20, 2011

COSMETIC USE OF MICROORGANISM(S) sensations of itching or pruritus, resulting in scratching FOR THE TREATMENT OF SCALP behaviour which amplifies the phenomenon of appearance of DISORDERS the dandruff. 0009. The dandruff conditions of the scalp may be of CROSS REFERENCE TO RELATED greasy or oily type or of dry type. APPLICATIONS 0010. The dry dandruff conditions of the scalp are more 0001. This application claims priority to French Patent frequently manifested and are amplified during skin hydra Applications No. 08 57865, filed Nov. 19, 2008, and No. 09 tion disorders, and especially during Substantial dryness of 53611, filed Jun. 2, 2009, and U.S. Provisional Patent Appli the epidermis of the scalp. Thus, the treatment of dry dandruff cations No. 61/084,582, filed Jul. 27, 2008, and No. 61/213, conditions, and the Solving of the unattractive manifestations 217, filed Jun. 16, 2009, the disclosures of which are incor thereof, involve being able to sufficiently rehydrate the scalp. porated herein by reference in their entireties. 0011 Besides, as indicated above, the scalp is rich in BACKGROUND OF THE INVENTION sebaceous glands. It has been observed that dandruff develops more easily in the excessive presence of sebum and is more 0002 1. Field of the Invention readily pruritic. Sebum secretion is a normal phenomenon 0003. The present invention aims principally to propose a which is useful for the skin and for the head of hair. Sebum new active agent for the prevention and/or treatment of scalp protects the scalp and gives the haira sheen by lubricating the disorders, especially aesthetic disorders. In particular, the cuticle. However, hypersecretion of sebum, or seborrhoea, present invention relates to dandruff disorders of the scalp, in may lead to disruptions, annoyances, sensations or feelings of particular of a greasy scalp. The present invention is also discomfort, aesthetic disorders, or even a skin pathology. directed towards proposing a novel cosmetic process for pre Thus, an excessive secretion of sebum promotes the appear venting and/or treating a dandruff condition of the scalp. The ance of a greasy or oily dandruff condition of the scalp or present invention also relates to an assembly or kit that is greasy or oily dandruff. suitable for use in a process of the invention. The present 0012. It has also been recently demonstrated that yeast of invention also relates to the field of topical products, food Malassezia type have a Substantial lipase activity, resulting in Supplements or functional foods intended for Scalp care. the hydrolysis of sebum triglycerides so as to give fatty acids. 0004 2. Discussion of the Background These fatty acids are then capable of causing dandruff condi 0005. The scalp is an epidermis that undergoes continual tions in sensitive individuals, i.e. individuals having an renewal, like the rest of the cutaneous tissue, and that is rich impaired barrier function, and therefore more particularly in Sebaceous glands. Normally, the scalp is renewed by susceptible to the destructive action of fatty acids on the imperceptible, non-visible elimination of the superficial skin cutaneous barrier. cells. However, excessive renewal of the cells of the stratum 0013 Thus, the greater the presence of sebum, the more corneum of the scalp, for various reasons, may result in the readily oily dandruff develops. Moreover, it has a tendency to formation of large, thick patches of cells which are visible to be more readily pruritic. the naked eye, known as "dandruff. 0006 Various factors may promote the onset of dandruff. 0014 Dandruff conditions generally respond to various For example, mention may be made of stress, the winter local or systemic treatments. For example, various prepara period, an excess of sebum, a hydration defect or colonization tions comprising antimicrobial agents or keratolytic agents or of the skin or of the hair follicles by yeasts of the Malassezia keratinization regulators are commonly proposed for treating spp. type. These factors especially have the common feature dandruff conditions. In particular, preparations combining of causing or promoting skin inflammation. Such an inflam antifungal and anti-seborrhoeic agents have been proposed in mation reinforces the appearance or even increases the pres order to treat severe dandruff conditions, in particular greasy ence of dandruff. or oily dandruff conditions. The antifungal-based treatments 0007. The Malassezia sp. genus is constituted of lipophilic demonstrate certain effectiveness on oily dandruff condi yeast normally present on human skin and on the skin of tions. certain warm-blooded animals. The distribution thereof 0015. However, the efficacy of these treatments is only depends on age, on Sebaceous gland activity and on certain Suspensory and demands rigorous adherence on the part of pathologies. The Malassezia sp. yeast represents approxi the user (frequency of use and Sufficient application time). mately 45% of the normal commensal flora at the surface of Now, daily and long-term use of these treatments may lead to the scalp in individuals without dandruff, but can represent a phenomenon of dependence that reduces their efficacy. The 75% of the flora in the case of dandruff, and up to 85% in the dependence may be associated with a rebound phenomenon case of associated seborrhoeic dermatitis. The other microor occurring when the treatment is stopped. The rebound phe ganisms present at the Surface of the scalp are micrococci and nomenon is generally manifested by hyperseborrhoea or pru Propionobacterium. Imbalance of the scalp ecoflora is a fac ritus, which are paradoxically liable to worsen the dandruff tor that promotes or even reinforces the presence of dandruff. condition by impairing the barrier function of the scalp. 0008 Dandruff conditions are chronic, frequent, recurring 0016. Moreover, the aggressiveness of certain antidan conditions that are socially incapacitating Owing to their obvi druff active agents with respect to the epidermal cells or the ous unattractive nature. Many factors can amplify these phe Scalp ecoflora may also affect the scalp's barrier functions and nomena and result in the appearance of additional disorders, lead to worsening of the dandruff condition. Such as inflammatory conditions of the scalp. These dandruff 0017. Unpleasant side effects, such as heating or irritation conditions and/or inflammatory conditions of the scalp are phenomena, may also be manifested during the use of these reflected by an impairment of the barrier function of the treatments. These side effects may also be reflected by poor epidermis. What is more, these conditions may give rise to adherence to the treatments, thus reducing their efficacy. US 2011/0014248 A1 Jan. 20, 2011

0018. In addition, most of the active agents usually used 0035 Finally, there is still a need for a treatment for dan for treating dandruff often have an unpleasant odour that also druff conditions that is efficient and simple, and that can be reduces the adherence to the treatment. performed in a prolonged or repeated manner without wors 0019 Finally, the efficacy of antidandruff treatments is ening the dandruff condition. often slow to develop and requires rigorous application over 0036. The object of the present invention is to satisfy these the long term. This lag time often leads to failure to follow the needs. treatment. 0037 Thus, according to one object, the invention relates 0020 Consequently, many failures occur in the use of to the cosmetic use of an effective amount of at least one these treatments and can usually be attributed to the following probiotic microorganism, in particular of the Lactobacillus factors: protocol not properly followed; frequency of use not sp. and/or Bifidobacterium sp. genus, of a fraction thereof adhered to; non-cosmetic appearance of the product; irrita and/or of a metabolite thereof, as an agent for preventing tion by the washing base; application time not properly and/or treating scalp disorders, and in particular dandruff adhered to; lassitude. conditions of the scalp. 0038 According to another of its aspects, a subject of the invention is a method, in particular a cosmetic method, for SUMMARY OF THE INVENTION treating and/or preventing aesthetic disorders of the scalp in 0021. There remains therefore a need to have new active an individual, comprising at least one step of administering, agents capable of exerting a beneficial cosmetic or therapeu to said individual, at least an effective amount of at least one tic action on Scalp conditions. probiotic microorganism, in particular of the Lactobacillus 0022. There also remains a need to have active agents for and/or Bifidobacterium sp. genus, and/or a fraction thereof, re-establishing the ecoflora of the scalp, and in particular for and/or a metabolite thereof. 0039. A method of the invention is in particular advanta preventing excessive colonization of the scalp by Malassezia geously implemented in individuals having a dandruff con Sp. dition of the scalp. 0023 There also exists a need to have new compositions 0040. A cosmetic treatment method of the invention may which are effective for preventing and/or treating oily or dry be implemented in particular by administering a cosmetic Scalp conditions, and which are pleasant and comfortable to and/or dermatological composition or combination of the use, thus promoting compliance with the treatment. invention, according to the customary technique for using 0024. There also exists a need to have new active agents these compositions. For example: applications of creams, for preventing and/or treating pruritic conditions and sebor gels, Sera, lotions, milks for removing make-up or of afterSun rhoeic dermatitis of the scalp. compositions to the keratin material Such as the skin or dry 0025. There also exists a need to have new active agents hair, application of a hair lotion to wet hair or of shampoos, as for preventing and/or treating inflammatory conditions of the regards topical application. Scalp. 0041. A cosmetic method according to the invention may 0026. There also exists a need to have new active agents thus be implemented by topical, for example daily, adminis for hydrating the scalp, and for reinforcing its barrier-func tration of a composition under consideration according to the tion properties. invention. 0027. There is also still a need for novel cosmetic treat 0042. A method according to the invention may comprise ments for preventing, reducing and/or treating dandruff con a single administration. According to another embodiment, ditions of the scalp, which are efficient and free of side effects the administration is repeated, for example, 2 to 3 times daily liable to adversely affect good compliance. for one day or more, and generally for a Sustained period of at 0028. There is also a need for a treatment for dandruff least 4 weeks, or even 4 to 15 weeks, with, where appropriate, conditions of the scalp whose efficacy is manifested rapidly one or more periods of interruption. and durably over time. 0043. Thus, according to another subject, the invention 0029. There is also a need for a treatment for dandruff relates to a cosmetic process for preventing and/or treating a conditions of the scalp that is more efficient than the existing dandruff condition of the scalp, the said process comprising treatmentS. the administration of an effective amount of at least a first 0030 There is also a need for a treatment for dandruff cosmetic active agent over a first and second consecutive conditions of the scalp that does not adversely affect the periods of time, the said periods of time together forming a ecoflora of the scalp, or even that reinforces the presence of a sequence, and of at least a second cosmetic active agent, healthy ecoflora. topically, over a single period of time chosen from the first and the second period of time, the said first and second cos 0031. There is also a need for a treatment for dandruff metic active agents being formulated in separate composi conditions that is capable of maintaining, or even reinforcing, tions, the first cosmetic active agent being chosen from pro the hydration of the scalp. biotic microorganisms, a fraction thereof and/or a metabolite 0032. There is a need for a treatment for dandruff condi thereof, and mixtures thereof, and the second cosmetic active tions that is capable of maintaining, or even reinforcing, the agent being chosen from antidandruff active agents. barrier properties of the scalp. 0044) Unexpectedly, the inventors have observed that a 0033. There is a need for treatments for dandruff condi probiotic microorganism, in particular of the Lactobacillus tions that are free of the abovementioned side effects, and in sp. and/or Bifidobacterium sp. genus, makes it possible to particular that do not induce hyperseborrhoea, seborrhoeic reduce dandruff conditions by acting on the hydration and on dermatitis or pruriginous conditions. the barrier function of the scalp. 0034. There is also a need for a treatment for dandruff 0045. The use of such a microorganism promotes optimi conditions that does not induce inflammation. zation of the assimilation of the nutrients provided by the diet, US 2011/0014248 A1 Jan. 20, 2011

at the level of the intestinal mucosa, and contributes to pro mation, the maintenance of a balanced barrier, integrity of the moting the provision of nutrients essential to cell metabolism barrier and conservation of a balanced ecoflora. and to the synthesis of the various functional and structural 0056. The scalp is less irritated and pruriginous, less frag elements of the skin. ile and more hydrated, and the level of dandruff is reduced. 0046. Thus, the reinforcement of the barrier functions of 0057 Such a sequence of steps also makes it possible to the skin makes it possible to reduce the inflammatory condi accelerate the onset of efficacy of the antidandruff treatment tions of the skin, to maintain a balanced barrier and the and to amplify the intensity of its beneficial effects. integrity thereof, and to preserve a balanced ecoflora. 0058. The administration of a probiotic microorganism 0047. The scalp is then less irritated and pruriginous, less alone for maintaining or improving the condition of skin or fragile and more hydrated, and the dandruff conditions are animal fur (WO 01/17365) or, where appropriate, in combi reduced. nation with the topical administration of an associated cos 0048 Also, unexpectedly, the inventors have observed metic active agent to improve the appearance of skin tissues that the administration over a period of time of a probiotic (WO 2006/104730) has been proposed. microorganism, especially of the genus Lactobacillus sp., and 0059 Advantageously, the use of probiotic microorgan in particular Lactobacillus paracasei, especially orally, with isms according to the invention, especially of the Lactobacil an antidandruff active agent topically, especially Zinc lus and/or Bifidobacterium sp. genus, and in particular the pyrithione, this administration being preceded or followed, Lactobacillus paracasei ST11 strain, a fraction thereofand/or and in particular followed, by the administration, over a metabolite thereof, makes it possible to restore a healthy another period of time, of the probiotic microorganism, in the Scalp, in perfect homeostasis, and to re-establish a balanced absence of the antidandruff active agent, makes it possible to ecoflora. efficiently reduce dandruff conditions of the scalp without 0060 A composition of the invention may advantageously manifestation of side effects, such as pruriginous conditions, make it possible to re-establish a balanced ecoflora via the seborrhoeic dermatitis or inflammation. induction of epidermal defence proteins. 0061 According to another advantage, a use according to 0049. The efficacy of this treatment is manifested more the invention may reduce and/or treat pruritis of the scalp quickly, and more intensely, compared with the isolated use Subsequent to the presence of irritant metabolites resulting of these cosmetic active agents. from sebum lipid metabolism by Malassezia sp. 0050 Also, the administration over a period of time of a 0062 According to another advantage, a process or a use probiotic microorganism, especially orally, with, as topical according to the invention may promote hydration and main antidandruff active agent, another probiotic microorganism, tenance of the integrity of the scalp. this administration being preceded or followed by the admin 0063 Also, advantageously, a process of the invention istration over another period of time of the first probiotic makes it possible to reduce the period of application of anti microorganism in the absence of the antidandruff active dandruffactive agents the risk of side effects arising, while at agent, makes it possible to accelerate the establishment of the the same time maintaining or even reinforcing their activity. beneficial effects of the antidandruff treatment and to 0064. A process of the invention advantageously makes it increase, or even amplify, the intensity of its effects. possible to accelerate the establishment of the beneficial 0051. The inventors have especially observed that after a effects of the antidandruff treatment to amplify their intensity. treatment of the invention, the presence of dandruff is greatly 0065. A process of the invention also advantageously reduced, or even nonexistent, and that the scalp's barrier makes it possible to restore a healthy scalp, in perfect homeo properties are reinforced. Stasis, and to re-establish a balanced ecoflora. 0052. Thus, surprisingly, the oral administration of probi 0066 According to another advantage, a process accord otic microorganisms, in particular lactic acid probiotic micro ing to the invention makes it possible to reduce and/or treat organisms, promoting the assimilation of nutrients that are scalp pruritus following the use of irritant antidandruff active essential for cell metabolism by the intestinal mucosae, is agents. capable of remotely preventing the deleterious effects oftopi 0067. According to another of its aspects, the present cally applied antidandruff active agents and of reinforcing invention relates to the use of an effective amount of at least their efficacy, or even of giving rise to a synergistic effect on one probiotic microorganism, in particular of the Lactobacil the prevention, reduction and/or treatment of dandruff. lus sp. and/or Bifidobacterium sp. genus, and/or a fraction 0053. The surprising effect of the process according to the thereof and/or a metabolite thereof, for preparing a pharma invention results from the use, for the first time by the inven ceutical or dermatological composition for preventing and/or tors, of two treatment steps, i.e. a first step including the treating inflammation of the scalp. administration, over a period of time, of a probiotic microor 0068. The pharmaceutical or dermatological composition ganism and an antidandruff active agent, this agent being is prepared by admixing said at least one probiotic microor administered topically, followed or preceded, in particular ganism with at least one pharmaceutical or dermatological followed, by a second step including the administration, over excipient. another period of time, of the probiotic microorganism in the 0069. In particular, such a composition is found to be absence of the antidandruff active agent. effective for treating conditions of dryness or xerosis of the 0054. Such a sequence of steps makes it possible advan scalp, pruritis of the scalp or seborrhoeic dermatitis of the tageously to Substantially reduce, or even to eliminate, the Scalp. side effects of antidandruff active agents while at the same 0070 A composition of the invention can advantageously time reinforcing the beneficial effects of the probiotic micro be used for preventing and/or treating skin infections, and in organism on the barrier properties of the scalp. particular of the scalp, by Malassezia sp. 0055. The protection and reinforcement of the barrier 0071. A use in accordance with the invention may also properties of the scalp allow a reduction of the skin inflam comprise the use of at least an effective amount of at least a US 2011/0014248 A1 Jan. 20, 2011 first probiotic microorganism, in particular of the Lactobacil I0082. According to another of its aspects, a subject of the lus or Bifidobacterium sp. genus, and/or a fraction thereof, invention is a cosmetic use of at least an effective amount of and/or a metabolite thereof, in combination with an effective at least a first and a second cosmetic active agent, the said first amount of at least a second microorganism, in particular a cosmetic active agent being Lactobacillus paracasei, a frac probiotic microorganism, distinct from said first probiotic tion thereof and/or a metabolite thereof, and the second active microorganism. agent being chosen from antidandruffactive agents and being 0072 For the purpose of the invention, the expression administered topically, for preventing and/or treating a dan “distinct from said first probiotic microorganism' means that druff condition of the scalp. it is possible to distinguish, in the composition, either two I0083. The first and second cosmetic active agents are each different microorganisms, or two different forms of the same formulated in a first and second cosmetic composition that are microorganism. Thus, when the second microorganism is, for different from each other. example, of the Lactobacillus or Bifidobacterium sp. genus and corresponds to the same species as that of the invention, BRIEF DESCRIPTION OF THE DRAWINGS this second microorganism is then presentina form other than I0084. A more complete appreciation of the invention and the first microorganism. many of the attendant advantages thereof will be readily 0073. According to another of its aspects, the present obtained as the same become better understood by reference invention relates to a cosmetic and/or dermatological compo to the following detailed description when considered in con sition that is of use for preventing and/or treating scalp dis nection with the accompanying drawings, wherein: orders, in particular oily dandruff conditions of the scalp. I0085 FIG. 1 illustrates the clinical evaluation of the pres comprising, in a physiologically acceptable carrier, at least an ence of loose dandruffin individuals treated with Maltodex effective amount of at least one probiotic microorganism, in trin (A) or 1x10 cfu/g Lactobacillus paracasei ST11 particular of the Lactobacillus sp. and/or Bifidobacterium sp. (CNCM 1-2116) (B): genus, and/or a fraction thereofand/or a metabolite thereof, in I0086 FIG. 2 illustrates the clinical evaluation of the pres combination with an effective amount of at least one active ence of adherent dandruffin individuals treated with Malto agent chosen from an antiseborrhoeic active agent, a hydrat dextrin (A) or 1x10 cfu/g Lactobacillus paracasei ST11 ing active agent and an antidandruff active agent, and mix (CNCM I-2116) (B): tures thereof, in particular as described hereinafter. I0087 FIG.3 illustrates the clinical evaluation of erythema 0074 According to one variant embodiment of the inven in individuals treated with Maltodextrin (A) or 1x10 cfu/g tion, a microorganism according to the invention may be used Lactobacillus paracasei ST11 (CNCM 1-2116) (B); and orally. I0088 FIG. 4 illustrates the results of measuring the pres 0075 According to another variant embodiment of the ence of the yeast Malassezia sp. in individuals treated with invention, the microorganism according to the invention may Maltodextrin (A) or 1x10 cfu/g Lactobacillus paracasei be used topically. ST11 (CNCM I-2116) (B). 0076. As specified hereinafter, the compositions contain ing a microorganism according to the invention are formu DETAILED DESCRIPTION OF THE PREFERRED lated so as to be compatible with the selected method of EMBODIMENTS administration. I0089 For the purpose of the present invention, the term 0077. The invention relates to the use of a microorganism “effective amount’ is intended to mean an amount sufficient in accordance with the invention in the form of a cosmetic or to obtain the expected effect, namely, in particular, the pre dermatological or pharmaceutical composition. vention, reduction and/or treatment of dandruff conditions. 0078. According to another embodiment, in a process of 0090. For the purposes of the present invention, the terms the invention the first cosmetic active agent is administered “prevent' or “preventing” mean totally eliminating or par orally or topically, and in particular orally. tially reducing the risk of manifestation of a given phenom 0079 According to another embodiment, in a process of enon, i.e. in the present invention the presence of dandruff. the invention the second cosmetic active agent is preferably “Partial reduction' implies that the risk remains but to a lesser administered over the first period of time. degree than before the implementation of the invention. 0080 According to another embodiment, a process 0091 Dandruff Conditions according to the invention may advantageously be Suitable for 0092. As indicated previously, a scalp presenting exces preventing and/or treating a dandruff condition of the scalp sive dryness or excessive secretion of sebum may manifest a associated with dryness or Xerosis of the scalp, hypersebor dandruff condition, which, depending on the case, may be rhoea of the scalp, an imbalanced ecoflora, pruritus, inflam characterized by the presence of dry or greasy or oily dan mation of the scalp, or an imbalanced barrier function of the druff, or even pruritis and/or an inflammation of the epider Scalp. mis. 0081. According to another of its aspects, the present (0093 Dry dandruff conditions reflect a xerosis of the invention relates to a cosmetic assembly comprising at least a Scalp, which may be combined with excessively rapid first and a second cosmetic composition, the first composition renewal of its stratum corneum. Dry dandruff flakes are gen comprising at least an effective amount of at least a first erally in the form of Small and white or grey, and are spread cosmetic active agent, the said first cosmetic active agent over the scalp and on the clothing, giving rise to an unaes being Lactobacillus paracasei, a fraction thereof and/or a thetic visual effect. metabolite thereof, and the second composition comprising at 0094. The itching associated with dryness of the scalp may least an effective amount of at least a second cosmetic active lead to erythema, pruritus or even inflammation. agent chosen from antidandruff active agents and being 0.095 Greasy or oily dandruff conditions are one of the administered topically. forms of seborrhoeic dermatitis. US 2011/0014248 A1 Jan. 20, 2011

0096 Individuals suffering therefrom have an erythema 0117 Process tous scalp covered with large, greasy or oily, yellow scales 0118. A process according to the invention includes at which accumulate so as to form packets. They have a pruritic least two periods of time, which are consecutive to each other, Scalp, and often have burning sensations on the affected areas. together forming a sequence known as the “treatment 0097. These phenomena may be amplified by the presence sequence'. of pathogenic microorganisms, especially Malassezia sp. 0119) A process according to the invention includes at These microorganisms having the property of releasing fatty least a first treatment sequence, or even a succession of sev acids from the sebum may impair the barrier function of the eral sequences, for example at least two, three or four con epidermis and give rise to inflammation. secutive treatment sequences. 0098. During dandruff conditions of the scalp, the cutane 0.120. A treatment sequence may thus be repeated so as to ous barrier is unbalanced, its integrity and its hydration are obtain a Succession of first and second periods of time. impaired, and its ecoflora is disturbed. The skin of the scalp is 0121 Advantageously, a process of the invention includes irritated and pruritic, brittle, less hydrated, and sensitive to a sequence repeated at least once, in particular at least twice infections. and preferably at least three times. 0099. The use of a probiotic microorganism, in particular 0.122 Alternatively, the succession of the treatment of the Lactobacillus and/or Bifidobacterium sp. genus, in sequences may include between each sequence a phase of accordance with the invention results in the hydration and the stopping the treatments, ranging from a few days, for example ecoflora of the scalp being re-established and in the pruritis of 1, 2, 3, 4 or 5 days, to a few weeks, for example 1, 2, 3 or 4 the scalp being decreased. weeks. 0100. The use of a probiotic microorganism in accordance I0123. The first and second periods of time may range from with the invention via the oral route with an antidandruff a few days, for example 2, 3, 4, 5, 6 or 7 days, to a few weeks, active agent via the topical route, especially over two periods for example 2, 3, 4, 5 or 6 weeks. of time as defined hereinbelow, leads to re-establishment of 0.124. According to one embodiment, the two periods of the hydration and of the ecoflora and to a decrease in the time may range, independently of each other, from one week pruritus of the scalp. to six weeks, preferably from two to five weeks and prefer 0101 This decrease is reflected by a reduction in the entially from three to four weeks. phases of Scratching the scalp and a reduction in the impair 0.125. According to one embodiment, the first and second ment of the barrier function resulting therefrom. In addition, periods of time may be of different duration. For example, the the efficacy of the treatment is markedly improved and is first period of time may be shorter than the second, or, con developed much more quickly. versely, the second period of time may be shorter than the 0102 The skin is then less irritated andless pruritic and the first. presence of the dandruff is reduced, or even eliminated. I0126. According to another embodiment, the first period 0103 The uses, processes and compositions according to of time is equal to the second period of time. I0127. The administration of the active agents is performed the invention thus prove to be most particularly effective: at least once per period of time. Preferably, the periods of time 0104 for preventing and/or treating scalp disorders, in may be broken into units of time, in particular of equal dura particular aesthetic disorders, associated with excessive tion, for example into days or weeks. In Such an embodiment, dryness, or even Xerosis, the administration of the active agents is performed at least 0105 for preventing and/or treating scalp disorders, in once per unit of time, for example at least once a day. particular aesthetic disorders, associated with excess I0128. As indicated previously, the first cosmetic active sebum excretion and/or secretion, agent is administered over the two periods of time, whereas 0106 for preventing and/or treating dandruff condi the second cosmetic active agent is administered only over a tions, whether they are dry or greasy or oily, of the scalp. single period of time chosen between the first and the second 0107 for preventing and/or treating pruritis and/or seb period of time. orrhoeic dermatitis of the scalp, 012.9 Advantageously, the second cosmetic active agent 0.108 for re-establishing a balanced ecoflora of the may be administered over the first period of time. Scalp. 0.130 Thus, according to one preferred embodiment of the 0109 for improving and/or re-establishing the antimi invention, a process of the invention may include a first period crobial defences of a dry or a greasy or an oily scalp. of time including the administration of the first and second 0110 for improving the comfort of the skin and the cosmetic active agents, the said first period of time being Scalp. followed by a second period of time including the adminis 0111 for improving the hygiene and/or care of the tration of the first cosmetic active agent in the absence of the Scalp. second cosmetic active agent. I0131. According to yet another embodiment, a process of 0112 for giving the scalp a feeling of well-being, the invention may include a first period of time including the 0113 for maintaining and/or restoring the biomechani administration of the first cosmetic active agent in the absence cal properties of the scalp, of the second cosmetic active agent, the said first period of 0114 for preserving and/or reinforcing the integrity of time being followed by a second period of time including the the barrier functions of the skin of the scalp, administration of the first and second cosmetic active agents. 0115 for preventing and/or treating pruritus and/or seb 0.132. When the first cosmetic active agent is administered orrhoeic dermatitis associated with dandruff conditions in the absence of the second cosmetic active agent over a of the scalp, and period of time, it may be administered via any route known to 0116 for preventing and/or treating the inflammations those skilled in the art, especially orally or topically, and in associated with dandruff conditions of the scalp. particular orally. US 2011/0014248 A1 Jan. 20, 2011

0133. Since the first and second cosmetic active agents are 0146 The lysate used is thus totally or partially formed formulated in separate compositions, when they are admin from the intracellular biological constituents and from the istered over the same period of time, they may be adminis constituents of the cell walls and membranes. tered via identical or different routes of administration. In 0147 Advantageously, a lysate used for the invention may particular, the second cosmetic active agent is administered topically, and the first cosmetic active agent may be admin be the whole lysate obtained via lysis of the microorganism istered orally or topically, and preferably orally. under consideration. 0134. When they are administered over the same period of 0.148. This cell lysis may be accomplished via various time, the first and second cosmetic active agents may be techniques, such as an osmotic shock, a heat shock, via ultra administered sequentially over time, i.e. consecutively one Sonication, or alternatively under a mechanical stress of cen after the other, separately, i.e. each at a given moment of the trifugation type. period of time, or concomitantly. 0149 More particularly, this cell lysate may be obtained 0135 Within the same period of time, the first and second according to the technique described in U.S. Pat. No. 4,464, cosmetic active agents may be administered, without prefer 362, and especially according to the following protocol. ence, in any order, for example the first active agent before the 0150. In particular, a lysate of the invention may be second, or the second before the first active agent. obtained via ultrasonic disintegration of a medium compris 0136. During a concomitant administration, the topical ing probiotic microorganisms in order to release therefrom administration of the second cosmetic active agent is prefer the cytoplasmic fractions, the cell wall fragments and the ably performed first so as to be in place during the oral products derived from metabolism. All the components in administration of the first cosmetic active agent. their natural distribution are then stabilized in a weakly acidic 0.137 According to one preferred embodiment, the first aqueous Solution. period of time covers four weeks and includes the adminis tration of the first and second active agents once a day, and the 0151. Alysate may be used in various forms, in the form of second period of time covers four weeks and includes the a solution or in a pulverulent form. administration of the first active agent once a day, and stop 0152 The microorganism(s) may be included in a compo page of the second active agent. sition according to the invention in live, semi-active or inac 0138 Probiotic Microorganisms tivated or dead form. 0139 For the purposes of the present invention, the term 0153. For the purposes of the invention, an “inactivated “probiotic microorganisms’ means a live microorganism or “dead microorganism is a microorganism that is no longer which, when consumed in adequate amount, has a positive capable of forming colonies in cultures. The dead or inacti effect on the health of its host ("Joint FAO/WHO Expert vated microorganisms may have intact or broken cell mem Consultation on Evaluation of Health and Nutritional Prop branes. The dead or inactivated microorganisms may be erties of Probiotic in Food Including Powder Milk with Live obtained via any method known to those skilled in the art. Lactic Acid Bacteria, 6 Oct. 2001), and which may in par 0154 According to one embodiment, a probiotic microor ticular improve the intestinal microbial balance. ganism that is Suitable for a use and in particular for a process 0140. According to one variant of the invention, a micro of the invention may be chosen from Lactobacillus sp., Bifi organism according to the invention may be used in an iso dobacterium sp., Cocci, yeasts and sporulated bacteria, and lated form, i.e. not mixed with one or more compound(s) mixtures thereof. liable to be associated with it in its medium of origin. 0155 Preferably, a microorganism suitable for a use 0141 For the purposes of the invention, the term “metabo according to the invention is a probiotic microorganism, in lite' denotes any substance derived from the metabolism of particular of the Lactobacillus and/or Bifodobacterium sp. the microorganisms under consideration according to the genus. invention and also having efficacy in the treatment of dandruff 0156 According to one embodiment, a microorganism conditions of the scalp. that may be suitable for the invention, and in particular for a 0142 For the purposes of the invention, the term “frac process of the invention, may be preferentially chosen from tion more particularly denotes a fragment of the said micro ascomycetes such as Saccharomyces, Yarrowia, Kluyveromy organism, which has efficacy in the treatment of dandruff ces, Torulaspora, Schizosaccharomyces pombe, Debaromy conditions of the Scalp by analogy with the said whole micro ces, Candida, Pichia, Aspergillus and Penicillium, bacteria of organism. the genus Bifidobacterium, Bacteroides, Fusobacterium, 0143 According to one preferred embodiment, the probi Melissococcus, Propionibacterium, Enterococcus, Lactococ otic microorganism metabolites and/or fractions that are Suit cus, Staphylococcus, Peptostrepococcus, Bacillus, Pediococ able for use in the invention may be administered in the form cus, Micrococcus, Leuconostoc, Weissella, Aerococcus, of a lysate. Oenococcus and Lactobacillus, and mixtures thereof. 0144. For the purposes of the invention, a “lysate' conven 0157. As ascomycetes most particularly suitable for the tionally denotes a material obtained after the destruction or present invention, mention may in particular be made of dissolution of biological cells via a phenomenon known as Yarrowia lipolitica and Kluyveromyces lactis, and likewise cell lysis, thus giving rise to the release of the intracellular Saccharomyces cereviseae, Torulaspora, Schizosaccharomy biological constituents naturally contained in the cells of the ces pombe, Candida and Pichia. microorganism under consideration. 0158. According to one embodiment, a probiotic microor 0145 For the purposes of the present invention, the term ganism that is Suitable for a use, and in particular in a process, “lysate' is used without preference to denote the whole lysate of the invention may be chosen from: obtained via lysis of the microorganism under consideration 0159 lactic acid bacteria: which produce lactic acid by or only a fraction thereof. fermentation of Sugar. US 2011/0014248 A1 Jan. 20, 2011

According to their morphology, they are divided up into two dobacterium infantis, Bifidobacterium adolescentis and groups: Bifidobacterium pseudocatenulatum, and mixtures thereof. 0160 Lactobacillus species: Lactobacillus acidophilus, 0170 The species most particularly suitable are Lactoba amylovorus, casei, rhamnosus, brevis, Crispatus, delbrueckii cillus johnsonii, Lactobacillus paracasei, Bifidobacterium (Subsp. bulgaricus, lactis), fermentum, helveticus, galli adolescentis and Bifidobacterium longum, respectively narum, gasserijohnsonii, plantarum, reuteri, salivarius, ali deposited according to the Treaty of Budapest with the Insti mentarius, curvatus, casei Subsp. casei, sake, and tut Pasteur (28 rue du Docteur Roux, F-75024 Paris cedex 15) 0161 Cocci. Enterococcus (faecalis, faecium), Lactococ on Jun. 30, 1992, Jan. 12, 1999, Apr. 15, 1999 and Apr. 15, cus lactis (Subsp. lactis or Cremoris), Leuconostoc mesenteroi 1999 under the following designations: CNCM I-1225, des Subsp. dextranicum, Pediococcus acidilactici, Sporolac CNCM I-2116, CNCM I-2168 and CNCM I-2170, and the tobacillus inulinus, Streptococcus salvarius Subsp. Bifidobacterium lactis (Bb 12) (ATCC27536) or Bifidobac thermophilus, Streptococcus thermophilus, Staphylococcus terium longum (BB536) genus. The Bifidobacterium lactis carnosus, Staphylococcus xylosus, (ATCC27536) strain can be obtained from Hansen (Chr. 0162 bifidobacteria or Bifidobacterium species: Bifido Hansen A/S, 10-12 Boege Alle, P.O. Box 407, DK-2970 bacterium adolescentis, animalis, bifidum, breve, lactis, Hoersholm, Denmark). longum, infantis, pseudocatenulatum, 0171 Advantageously, a microorganism that is Suitable for use in the invention may be a lactic acid probiotic micro 0163 yeasts: Saccharomyces (cerevisiae or boulardii), organism. 0164 other sporulated bacteria: Bacillus (cereus var 0172 According to one preferred embodiment, a probiotic toyo or subtilis), Bacillus coagulans, Bacillus licheni microorganism that is Suitable for use in the invention may in formis, Escherichia coli strain nissle, Propionibacte particular be a microorganism of the genus Lactobacillus sp. rium feudenreichii, 0173 According to one particular embodiment of the 0.165 and mixtures thereof. invention, the microorganism is other than a Lactobacillus 0166 As other examples of probiotic microorganisms that rhamnosus. are suitable for the invention, mention may be made of Bifi 0.174 Preferably, a microorganism of the Lactobacillus dobacterium adolescentis, Bifidobacterium animalis, Bifido sp. genus Suitable for the invention may be chosen from the bacterium bifidum, Bifidobacterium breve, Bifidobacterium species Lactobacillus johnsonii, Lactobacillus reuteri, Lac lactis, Bifidobacterium longum, Bifidobacterium infantis, tobacillus paracasei and Lactobacillus casei, and mixtures Bifidobacterium pseudocatenulatum, Lactobacillus acido thereof. philus NCFB 1748; Lactobacillus amylovorus, Lactobacillus 0.175. According to one preferred embodiment, a micro casei (Shirota), Lactobacillus rhamnosus strain GG, Lacto organism Suitable for the invention may be a Lactobacillus bacillus brevis, Lactobacillus crispatus, bulgaricus, Lacto paracasei. bacillus delbrueckii Subsp., lactis, Lactobacillus fermentum, 0176 A microorganism suitable for the invention may in Lactobacillus helveticus, Lactobacillus gallinarum, Lacto particular be the Lactobacillus paracasei ST11 strain depos bacillus gasseri, Lactobacillus johnsonii CNCM I-1225, ited according to the Treaty of Budapest with the Institut Lactobacillus plantarum, Lactobacillus reuteri, Lactobacil Pasteur (28 rue du Docteur Roux, F-75024 Paris cedex 15) on lus salivarius, Lactobacillus alimentarius, Lactobacillus cur Jan. 12, 1999 under the designation CNCM 1-2116, and/or a vatus, Lactobacillus casei Subsp. casei, Lactobacillus sake, fraction thereof and/or a metabolite thereof. Lactococcus lactis, Enterococcus faecalis, Enterococcus 0177 According to another preferred embodiment, a pro faecium, Lactococcus lactis Subsp. lactis, Lactococcus lactis biotic microorganism that is suitable for use in the invention Subsp cremoris, Leuconostoc mesenteroides Subsp. dextrani may in particular be a microorganism of the genus Bifidobac cum, Pediococcus acidilactici, Sporolactobacillus inulinus, terium sp., and in particular Bifidobacterium longum, espe Streptococcus salvarius Subsp. thermophilus, Streptococcus cially Bifidobacterium longum (BB536). thermophilus, Staphylococcus carnosus, Staphylococcus 0.178 Advantageously, a Bifidobacterium longum may be xylosus, Saccharomyces cerevisiae, Saccharomyces boular used in the form of a lysate, obtained especially as described dii, Bacillus cereus var. toyo, Bacillus cereus var. subtilis, above. Bacillus coagulans, Bacillus licheniformis, Escherichia coli 0179 A microorganism of the invention may be formu strain nissle and Propionibacterium feudenreichii, and mix lated in a composition in a proportion of at least 0.0001% tures thereof. expressed as dry weight, in particular in a proportion from 0167 More particularly, it may be a probiotic microorgan 0.0001% to 20% and more particularly in a proportion from ism chosen from Lactobacillus sp., Sporolactobacillus sp., 0.001% to 15% by weight, in particular from 0.01% to 10% Enterococcus sp., Lactococcus sp., Bacillus sp., Streptococ by weight and especially from 0.1% to 2% by weight relative cus sp., Pediococcus sp., Leuconostoc sp. and Bifidobacte to the total weight of the composition containing it. rium sp., and in particular chosen from Lactobacillus sp. and 0180. In general, a composition according to the inven Bifidobacterium sp., and mixtures thereof. tion, and in particular that intended to be administered orally, 0168 More particularly, a microorganism useful for the may comprise, for living microorganisms, from 10 to 10' invention may be a probiotic microorganism chosen from cfu/g, in particular from 10 to 10" cfu/g, and more particu Lactobacillus sp. and/or Bifidobacterium sp. larly from 107 to 10' cfu/g of microorganisms per gram of 0169. As illustrations of these probiotic microorganisms, carrier or Support, or at equivalent doses calculated for inac mention may be made more particularly of Lactobacillus tive or dead microorganisms or for microorganism fractions johnsonii, Lactobacillus reuteri, Lactobacillus rhamnosus, or for metabolites produced. Lactobacillus paracasei, Lactobacillus casei, Bifidobacte 0181. In particular, in a composition administered orally, rium bifidum, Bifidobacterium breve, Bifidobacterium lon the corresponding microorganism and/or fraction and/or gum, Bifidobacterium animalis, Bifidobacterium lactis, Bifi metabolite concentration may be adjusted so as to correspond US 2011/0014248 A1 Jan. 20, 2011

to doses (expressed as microorganism equivalent) ranging care or hygiene effect on the hair and/or the scalp, and in from 5x10 to 10" cfu/day and in particular from 10 to 10' particular may be intended for reinforcing the skin barrier. cfu/day. 0.197 According to one embodiment, a third or additional 0182. A composition for topical application according to cosmetic active agent Suitable for a process of the invention the invention may generally comprise from 10 to 10" cfu/g, may be chosen especially from a hair dyeing agent, an agent in particular from 10 to 10' cfu/g and more particularly for preventing hair loss and/or for promoting hair regrowth, a from 107 to 10 cfu/g of microorganisms. detangler, a hair shaping agent, an agent for preventing and/or 0183 The microorganism(s) may be included in a compo treating baldness, an anti-seborrhoea agent, an antibiotic, a sition according to the invention in a live, semi-active or hormone, an antiandrogen, an additional probiotic microor inactivated, or dead form. ganism, in particular a lysate of Bifidobacterium longum or of 0184. In the particular case of a topical administration, it Vitreoscilla filiformis, a hydrating agent, an antioxidant and a may be advantageous to use microorganisms in inactivated or Vitamin, and mixtures thereof. even dead form. 0198 Such a formulation may advantageously amplify the 0185. The microorganism(s) may also be included in the beneficial effects of a microorganism of the invention. form of fractions of cell components or in the form of metabo 0199 According to another embodiment, a topical or oral lites. The microorganism(s), metabolite(s) or fraction(s) may composition, or a combination according to the invention also be introduced in the form of a lyophilized powder, a may contain at least one active agent chosen from an antise culture Supernatant and/or, where appropriate, in a concen borrhoeic active agent, a hydrating active agent, an antidan trated form. druff active agent as described below, and/or mixtures 0186. When a composition comprises metabolites, the thereof. contents of metabolites in the compositions correspond Sub 0200. An additional or third cosmetic active agent may be stantially to the contents that may be produced by 10 to 10' chosen from: cfu, in particular 10 to 10" cfu and more particularly 107 to 0201 anti-seborrhoeic active agents. The term “antise 10" cfu of live microorganisms per gram of support or car borrhoeic active agent' is intended to mean a compound 1. capable of regulating sebaceous gland activity. The anti 0187 Expression of the amount of metabolites or fractions Seborrhoeic active agent is, for example, present in a of a microorganism in “cfu', or of dead microorganisms, is content ranging from 0.1% to 10% by weight, preferably intended to denote the amount of this microorganism that is from 0.1% to 5% by weight, and preferentially from necessary to produce the said amount of microorganism 0.5% to 3% by weight, relative to the total weight of the metabolites or fractions. composition. 0188 Cosmetic Active Agent 0202 As example of anti-seborrhoeic active agents one 0189 Additional Cosmetic Agent may mention certain Sulfur-containing amino acids, 13-cis 0190. According to one embodiment, a use of the inven retinoic acid, cyproterone acetate, benzoyl peroxide, Sulphur, tion, and in particular a process of the invention, implement vitamin B6 (or pyridoxine), selenium chloride, sea fennel; ing at least one probiotic microorganism in accordance with mixtures of extract of cinnamon, of tea and of octanoylgly the invention, and in particular of the Lactobacillus sp. and/or cine, such as Sepicontrol A5 TEAR) from Seppic; the mixture Bifidobacterium sp., may be made in combination with an of cinnamon, sarcosine and octanoylglycine sold in particular additional or a third cosmetic active agent. by the company SEPPIC under the trade name Sepicontrol 0191 Irrespective of the method of administration under A5(R); Zinc salts such as Zinc gluconate, Zinc pyrrolidonecar consideration, the effective amount of the microorganism of boxylate (or Zinc pidolate), Zinc lactate, Zinc aspartate, Zinc the invention, a fraction thereof and/or a metabolite thereof, carboxylate, Zinc salicylate, Zinc cysteate; copper derivatives, may also be advantageously combined with at least one other and in particular copper pidolate such as Cuivridone(R) from active agent. Solabia; extracts of plants of the species Arnica montana, 0.192 More particularly, according to one embodiment, a Cinchona succirubra, Eugenia caryophyllata, Humulus process according to the invention may include, besides the lupulus, Hypericum perforatum, Mentha piperita, Rosmari administration of the first and second cosmetic active agents nus officinalis, Salvia officinalis and Thymus vulgaris, all defined previously, the administration of at least a third or sold, for example, by the company Maruzen; extracts of additional cosmetic active agent. meadowsweet (Spiraea ulmaria) Such as the product sold 0193 A third cosmetic active agent may be administered, under the name Sebonormine(R) by the company Silab: without preference, over one or the other period of time extracts of the alga Laminaria saccharina Such as the product defined previously, or even over both periods of time. sold under the name Phlorogine(R) by the company Biotech 0.194. A third cosmetic active agent may be formulated marine; mixtures of extracts of salad burnet root (San together with the first and/or the second cosmetic active agent guisorba officinalis/Poterium officinale), of ginger rhizomes (s) defined previously, or may be formulated in a separate (Zingiber officinalis) and of cinnamon bark (Cinnamomum composition. cassia). Such as the product sold under the name Sebustop R. 0.195. When the third or additional cosmetic active agent is by the company Solabia; linseed extracts, such as the product formulated in a composition separate from the compositions sold under the name LinumineR by the company Lucas comprising the first and second cosmetic active agents, it may Meyer; Phellodendron extracts, such as those sold under the be administered orally or topically. The route of administra name Phellodendron extract BG(R) by the company Maruzen tion is chosen by a person skilled in the art so as to be more or Oubaku liquid B by the company Ichimaru Pharcos; mix particularly suited to the nature of the third cosmetic active tures of argan oil, of Serenoa serrulata (saw palmetto) extract agent. and of Sesame seed extract, such as the product sold under the 0196. Advantageously, such an additional or third cos name Regu SEBR) by the company Pentapharm; mixtures of metic active agent may be intended for exerting a cosmetic, extracts of willowherb, of Terminalia chebula, of nasturtium US 2011/0014248 A1 Jan. 20, 2011

and of bioavailable Zinc (microalgae). Such as the product 0205 hormones such as oestriol or analogues thereof, sold under the name Seborilys(R) by the company GreenTech; thyroxine and salts thereof; extracts of Pygeum afrianum, Such as the product sold under 0206 antiandrogens such as oxendolone, spironolac the name Pygeum afrianum sterolic lipid Extract(R) by the tone, diethylstilbestrol and flutamide company Euromed; extracts of Serenoa serrulata, such as 0207 hair dyeing agents: those sold under the name Viapure Sabal R) by the company 0208 detanglers; Actives International, or those sold by the company Euromed; 0209 hair shaping agents; mixtures of extracts of plantain, of Berberis aquifolium and of 0210 agents for preventing and/or treating baldness; Sodium salicylate, such as the product sold under the name 0211 antidandruff agents as detailed below, Seboclear(R) by the company Rahn: clove extract, such as the 0212 hydrating active agent. An hydrating active agent product sold under the name Clove extract Powder(R) by the is an active agent capable of reducing the state of dryness company Maruzen, argan oil. Such as the product sold under of an epidermis. the name Lipofructyl(R) by Laboratoires Sérobiologiques; lac 0213. The term “hydrating active agent' is intended to tic protein filtrates, such as the product sold under the name Ca Normaseb(R) by the company Sederma; extracts of the alga 0214) either a compound which acts on the barrier func Laminaria, such as the product sold under the name Lami tion, with a view to maintaining the hydration of the narghane(R) by the company Biotechmarine; oligosaccharides stratum corneum, or an occlusive compound. Mention of the alga Laminaria digitata, Such as the product sold under may be made of ceramides, sphingoid-based com the name Phycosaccharide ACR by the company Codificane pounds, lecithins, glycosphingolipids, phospholipids, Sugar extracts, such as the product sold under the name Poli cholesterol and its derivatives, phytosterols (Stigmas cosanol R by the company Sabinsa; Sulphonated shale oil, terol, B-sitosterol, campesterol), essential fatty acids, such as the product sold under the name Ichthyol Pale(R) by the 1,2-diacylglycerol, 4-chromanone, pentacyclic triterpe company Ichthyol; extracts of European meadowsweet (Spi nes, petroleum jelly and lanolin; raea ulmaria). Such as the product sold under the name 0215 or a compound which directly increases the water CytobiolRUlmaire by the company Libiol; sebacic acid, in content of the stratum corneum, Such as urea and its particular sold in the form of a sodium polyacrylate gel under derivatives, threalose and its derivatives, hyaluronic acid the name Sebosoft(R) by the company Sederma; glucoman and its derivatives, glycerol, pentanediol, pidolates, nans extracted from konjac tuber and modified with alkylsul serine, Xylitol, lactic acid and sodium lactate, glyceryl phonate chains, such as the product sold under the name polyacrylate, ectoin and its derivatives, chitosan, oli Biopol Beta R by the company Arch Chemical; extracts of gosaccharides and polysaccharides, cyclic carbonates, Sophora angustifolia, such as those sold under the name N-lauroylpyrrolidonecarboxylic acid and N-C-benzoyl Sophora Powder R or Sophora Extract(R) by the company L-arginine; Bioland; extracts of Cinchona succirubra bark, such as the 0216 or a compound which activates the sebaceous product sold under the name Red bark HS(R) by the company glands. Such as steroidal derivatives (including DHEA), Alban Muller; extracts of Ouillaia Saponaria. Such as the and vitamin D and its derivatives. product sold under the name Panama wood HS(R) by the 0217. These compounds may represent from 0.001% to company Alban Muller, glycine grafted onto an undecylenic 3%, and preferably from 0.01% to 20%, of the total weight of chain, such as the product sold under the name Lipacide UG the composition according to the invention. OR(R) by the company Seppic; the mixture of oleanolic acid 0218. By way of illustration of the urea derivatives, men and of nordihydroguaiaretic acid. Such as the product sold in tion may more particularly be made of hydroxyalkylurea the form of a gel under the name AC.Net(R) by the company derivatives, and in particular those described in document FR Sederma; phthalimidoperoxyhexanoic acid; tri(C-C) 2877 222. alkyl citrate sold under the name Cosmacol R. ECI by the 0219. According to one embodiment variant, a third or company Sasol, tri(C-Cs)alkyl citrate sold under the name additional cosmetic active agent useful in a process of the Cosmacol R. ECL by the company Sasol; 10-hydroxyde invention may be a microorganism referred to as a 'second canoic acid, and in particular mixtures of 10-hydroxyde microorganism', especially of probiotic type, and/or a frac canoic acid, of sebacic acid and of 1,10-decanediol. Such as tion thereof, and/or a metabolite thereof, which is different the product sold under the name Acnacidol R. BG by the from the said first microorganism defined as first cosmetic company Vincience; and mixtures thereof, active agent. 0203 agents for preventing hair loss and/or for promot 0220 According to one variant embodiment, the invention inghair regrowth such as nicotinic acid esters, especially relates to the use, in addition of a first probiotic microorgan including tocopheryl nicotinate, benzyl nicotinate and ism, for example as defined above, of the Lactobacillus and/ C-C alkyl nicotinates, for instance methyl or hexyl or Bifidobacterium sp. genus, of at least an effective amount nicotinate; pyrimidine derivatives such as 2,4-diamino of at least a second microorganism, in particular of probiotic 6-piperidinopyrimidine 3-oxide or Minoxidil described type, and/or a fraction thereof and/or a metabolite thereof, in U.S. Pat. No. 4,139,619 and U.S. Pat. No. 4,596,812: distinct from said first microorganism. Aminexil or 2,4-diaminopyrimidine 3-oxide, described 0221 For the purposes of the invention, as previously in WO 96/09048; agents that are both lipoxygenase exposed the expression “different from the said first probiotic inhibitors and cyclooxygenase inducers, or cyclooxyge microorganism' means that it is possible to distinguish within nase inducers that promote hair regrowth Such as those the same composition either two different microorganisms, or described in European patent application EP 0 648 488; two different forms of the same microorganism. Thus, when 0204 antibiotics such as macrollides, pyranosides and the second microorganism is, for example, of the genus Lac tetracyclines, and especially erythromycin; tobacillus sp. or Bifidobacterium sp. and corresponds to the US 2011/0014248 A1 Jan. 20, 2011

same species as that of the invention, this second microorgan CNCM I-1225, CNCM I-2168, CNCM I-2170 and CNCM ism is then present in a form different from the first microor I-3446, and the Bifidobacterium longum (BB536) genus, and ganism. mixtures thereof. 0222. The second probiotic microorganism may beformu 0236 According to one particular embodiment, the sec lated in the same composition as that containing the first ond probiotic microorganism is of the Lactobacillus species cosmetic active agent, or in the same composition as that genus, in particular of the species Lactobacillus johnsonii, a containing the second cosmetic active agent, or alternatively fraction thereof and/or a metabolite thereof. may be formulated in a third composition separate from the 0237. It may in particular be the species Lactobacillus above-mentioned compositions. johnsonii respectively deposited according to the Treaty of 0223) More particularly, it may be one of the probiotic Budapest with the Institut Pasteur (28 rue du Docteur Roux, microorganisms proposed hereinabove, as a specific example F75024 Paris cedex 15) on Jun. 30, 1992, under the designa of probiotic microorganisms for the first cosmetic active tion CNCMI-1225. agent or as 'second microorganism'. 0238 According to another particular embodiment, the 0224. This second microorganism may be chosen in par third or additional cosmetic active agent is a second probiotic ticular from ascomycetes Such as Saccharomyces, Yarrowia, microorganism of the genus Bifidobacterium sp., and in par Kluyveromyces, Torulaspora, Schizosaccharomyces pombe, ticular Bifidobacterium longum, especially Bifidobacterium Debaromyces, Candida, Pichia, Aspergillus and Penicillium, longum (BB536). bacteria of the Bacteroides, Fusobacterium, Melissococcus, 0239 According to one embodiment, when the third or Propionibacterium, Enterococcus, Lactococcus, Staphyllo additional cosmetic active agent is a second probiotic micro coccus, Peptostrepococcus, Bacillus, Pediococcus, Micro organism, it may advantageously be used in the form of a coccus, Leuconostoc, Weissella, Aerococcus, Oenococcus, lysate, especially obtained as described above. In particular, Lactobacillus or Bifidobacterium genus, and mixtures the second probiotic microorganism may be a lysate of Bifi thereof. dobacterium longum. 0225. According to one embodiment, the following bac 0240 According to yet another embodiment, a third or terial and yeast genera are preferentially used as second additional cosmetic active agent which may be an additional microorganism: microorganism Suitable for use in the invention may be cho 0226 lactic acid bacteria: Sen from non-photosynthetic filamentous bacteria and/or a 0227 Lactobacillus species: Lactobacillus acidophilus, fraction thereof and/or a metabolite thereof. These bacteria amylovorus, casei, rhamnosus, brevis, crispatus, delbrueckii may also be advantageously formulated in lysate form. (Subsp. bulgaricus, lactis), fermentum, helveticus, galli 0241. As illustrations of these bacteria, mention may be narum, gasserijohnsonii, plantarum, reuteri, salivarius, ali made especially of the non-photosynthetic filamentous bac mentarius, curvatus, casei Subsp. casei, sake, and teria as defined according to the classification in Bergey’s 0228 Cocci. Enterococcus (faecalis, faecium), Lactococ Manual of Systematic Bacteriology (Vol. 3, sections 22 and cus lactis (Subsp. lactis or Cremoris), Leuconostoc mesenteroi 23, 9th edition, 1989), among which mention may be made of des Subsp. dextranicum, Pediococcus acidilactici, Sporolac the bacteria belonging to the order of Beggiatoales, and more tobacillus inulinus, Streptococcus salvarius Subsp. particularly the bacteria belonging to the genus Beggiatoa, thermophilus, Streptococcus thermophilus, Staphylococcus Vitreoscilla, Flexithrix or Leucothrix. carnosus, Staphylococcus xylosus, 0242 Among the bacteria that may be used, mention may 0229 bifidobacteria or Bifidobacterium species: Bifido be made, for example, of Vitreoscilla filiformis (ATCC bacterium adolescentis, animalis, bifidum, breve, lactis, 15551), Vitreoscilla beggiatoides (ATTC 43181), Beggiatoa longum, infantis, pseudocatenulatum, alba (ATCC 33555), Flexithrix dorotheae (ATCC 23163), 0230 yeasts: Saccharomyces (cerevisiae or boulardii), Leucothrix mucor (ATCC 25107) and Sphaerotilus natans 0231 other sporulated bacteria: Bacillus (cereus var (ATCC 13338). toyo or subtilis), Bacillus coagulans, Bacillus licheni 0243 According to an embodiment of invention an addi formis, Escherichia coli strain nissle, Propionibacte tional or third active agent, for example contained in topical rium feudenreichii, or oral compositions, or combinations of the invention may be 0232 and mixtures thereof. an active agent in particular intended to reinforce the cutane 0233 More particularly, the second microorganism may ous barrier. be one of the probiotic microorganisms proposed above, by 0244. By way of additional or third active agents that can way of specific example of probiotic microorganisms for the be used, mention may be made of vitamins, such as vitaminA, first organism. B3, B5, B6, B8, C, D, E or PP; antioxidants, such as curcumi 0234. According to one particular embodiment, the third noids, carotenoids, polyphenol; inorganic (or minerals) com or additional cosmetic active agent is a second probiotic pounds; Sugars; amino acids; Sulfur-containing amino acids; microorganism of the genus Lactobacillus sp., in particular 3 and 6 polyunsaturated fatty acids; taurine and phytosterols. Lactobacillus johnsonii, a fraction thereof and/or a metabo 0245. In particular, use may be made of an antioxidant lite thereof. complex comprising vitamins C and E, and at least one caro 0235. The species most particularly suitable are Lactoba tenoid, especially a carotenoid chosen from B-carotene, lyco cillus johnsonii, Bifidobacterium adolescentis, Bifidobacte pene, astaxanthin, Zeaxanthin and lutein, flavonoids such as rium longum and Bifidobacterium lactis NCC 2818, respec catechins, proanthocyanidins, anthocyanins, ubiquinones, tively deposited according to the Treaty of Budapest with the coffee extracts containing polyphenols and/or diterpenes, Institut Pasteur (28 rue du Docteur Roux, F-75024 Paris extracts of chicory, extracts of ginkgo biloba, proanthocyani cedex 15) on Jun. 30, 1992, Jan. 12, 1999, Apr. 15, 1999, Apr. din-rich grape extracts, extracts of capsicum, Soya bean 15, 1999 and Jun. 7, 2005 under the following designations: extracts, other sources of flavonoids having antioxidant prop US 2011/0014248 A1 Jan. 20, 2011

erties, fatty acids, prebiotics, taurine, resveratrol, selenium 0256 An oral composition of the invention may comprise containing amino acids and glutathione precursors. other nutritional active agents chosen from: 0246 Among the flavonoids, catechins and OPCs (oligo 0257 anti-aging nutritional active agents, such as food meric proanthocyanidins) are preferably chosen. antioxidants, nutrients with free-radical-scavenging 0247. At least one prebiotic or a mixture of prebiotics may properties and cofactors of antioxidant endogenous also be involved. More particularly, these prebiotics may be enzymes, vitamins A, C and E. carotenoids, Xantho chosen from oligosaccharides, produced from glucose, galac phylls, isoflavones, certain minerals such as Zinc, cop tose, Xylose, maltose, Sucrose, lactose, starch, Xylan, hemi per, magnesium, selenium, lipoic acid, coenzyme Q10, cellulose or inulin, gums of acacia type for example, or a Superoxide dismutase (SOD) or taurine. Among the anti mixture thereof. More particularly, the oligosaccharide com aging active agents, mention may in particular be made prises at least one fructooligosaccharide. More particularly, of the unsaponifiable fractions extracted from lipids of this prebiotic may comprise a mixture of fructooligosaccha plant origin, Aloe Vera, native or hydrolysed marine ride and inulin. collagen, plant or marine oils rich in omega-3 and 0248. In the topical galenic forms, use may more particu omega-6 fatty acids (including gamma-linolenic acid), larly be made, as hydrophilic active agents, of proteins or 0258 photoprotective nutritional active agents such as: protein hydrolysates, amino acids, polyols, in particular C to antioxidants and free-radical scavengers, vitamins A, C Co polyols such as glycerol, Sorbitol, butylene glycol and and E. carotenoids, Xanthophylls, certain minerals such polyethylene glycol, urea, allantoin, Sugars and Sugar deriva as Zinc, copper, magnesium or selenium, coenzyme tives, water-soluble vitamins, starch, and bacterial extracts or Q10, Superoxide dismutase (SOD), plant extracts such as those of Aloe Vera. 0259 nutritional ingredients with hydrating or else 0249. As regards the lipophilic active agents, use may be immunomodulatory properties, such as extract of Poly made of retinol (vitaminA) and derivatives, tocopherol (vita podium leucotomos, and plant or marine oils rich in min E) and derivatives, ceramides, essential oils and unsa omega-3 and omega-6 fatty acids, including gamma ponifiable materials (tocotrienol, Sesamine, gamma-oryZa linolenic acid. nol, phytosterols, squalenes, waxes and terpenes). 0260 Antidandruff Active Agents 0250) As additional or third active agents that may also be 0261 A process according to the invention comprises a combined with the microorganism of the invention, with a use of an antidandruff agent. fraction thereof and/or with a metabolite thereof, in an oral 0262 According to another embodiment, a use of at least galenical formulation, any ingredient commonly used and/or one probiotic microorganism in accordance with the inven permitted may also be considered. tion, and in particular of the Lactobacillus sp. and/or Bifido 0251. By way of illustration, mention may be made of bacterium sp., may also comprise the use of an antidandruff Vitamins, minerals, essential lipids, trace elements, polyphe agent. nols, flavonoids, phytoestrogens, antioxidants such as lipoic 0263. The term “antidandruff active agent' is intended to acid and coenzyme Q10, carotenoids, prebiotics, proteins and mean a compound capable of preventing the appearance of amino acids, monosaccharides and polysaccharides, amino dandruff, decreasing the amount thereof and/or making it Sugars, phytosterols and triterpenic alcohols of plant origin. completely disappear. 0252. This may involve, in particular of vitamins A, C, D, 0264. An antidandruff active agent that is suitable for use E. PP and group B vitamins. Among the carotenoids, beta in the invention may be chosen especially from: carotene, lycopene, lutein, Zeaxanthin and astaxanthin are 0265 pyridinethione salts, especially the calcium, mag preferably chosen. The minerals and trace elements particu nesium, barium, strontium, zinc, cadmium, tin and Zir larly used are Zinc, calcium, magnesium, copper, iron, iodine, conium salts. The Zinc salt of pyridinethione is particu manganese, selenium and chromium (III). larly preferred. The zinc salt of pyridinethione is sold 0253 Among the polyphenol compounds, polyphenols especially under the name Zinc Omadine by the com from grape, from tea, from olive, from cocoa, from coffee, pany OLIN: from apple, from blueberry, from elderberry, from strawberry, 0266 trihalocarbamides of formula: from cranberry and from onion are also in particular selected. Preferably, among the phytoestrogens, isoflavones in free or glycosylated form are selected. Such as genistein, daidzein, Z NHCONH glycitein or alternatively lignans, in particular those from flax and from Schizandra chinensis. 0254 The amino acids or the peptides and the proteins C C containing them, such as taurine, threonine, cysteine, tryp tophan or methionine. The lipids preferably belong to the group of oils containing monounsaturated and polyunsatu 0267 in which Z represents a halogen atom such as chlo rated fatty acids Such as oleic acid, linoleic acid, alpha-lino rine or a C-C trihaloalkyl group Such as CF, lenic acid, gamma-linolenic acid, Stearidonic acid, long 0268 triclosan, represented by the formula: chain fish omega-3 fatty acids such as EPA and DHA, and conjugated fatty acids derived from plants or animals, such as CLAS (Conjugated Linoleic Acids). 0255 Thus, in particular a microorganism of the inven tion, a fraction thereof and/or a metabolite thereof, orally administered may also be combined with at least one nutri C OH tional active agent chosen from lycopene, Vitamin C, Vitamin E and polyphenol compounds. US 2011/0014248 A1 Jan. 20, 2011 12

0269 azole compounds such as climbazole, ketocona 0293. The compositions that are suitable for the invention Zole, clotrimazole, econazole, isoconazole and micona may be in any galenical form normally available for the Zole, selected mode of administration. 0270 antifungal polymers such as amphotericin B or 0294 The support or carrier may be of various nature, nystatin, depending on the type of composition under consideration. 0295. As regards more particularly the compositions for 0271 selenium sulfides, in particular those of formula external topical administration, they may be acqueous, aque SSes X ranging from 1 to 7. ous-alcoholic or oily solutions, solutions or dispersions of the 0272 sulfur in its various forms, such as cadmium sul lotion or serum type, emulsions of liquid or semi-liquid con fide, sistency, of the milk type, obtained by dispersion of a fatty 0273 allantoin, phase in an aqueous phase (O/W) or vice-versa (W/O), or 0274 coal or wood tars and derivatives thereof, in par Suspensions or emulsions of Soft, semi-solid or Solid consis ticular cade oil, tency, of the cream type, aqueous or anhydrous gels, micro (0275 salicylic acid, emulsions, microcapsules, microparticles, or vesicular dis persions of ionic and/or non-ionic type. 0276 undecylenic acid, 0296. These compositions are prepared according to the (0277 fumaric acid, usual methods. 0278 allylamines, such as terbinafine, 0297. These compositions may in particular constitute 0279 ciclopirox or octopirox, cleansing, protective, treatment or care creams, skincare 0280 piroctone olamine, lotions, gels or foams, such as cleansing or disinfecting 0281 clobetasol propionate or betamethasone Valerate, lotions, bath compositions or deodorant compositions. 0298. The compositions according to the invention may 0282 tea tree oil, also consist of solid preparations constituting cleansing soaps 0283 mixed oil of thyme and of catnip, or bars. 0284 an antidandruff probiotic or non-probiotic micro 0299 They may also be used for the scalp in the form of organism, especially a probiotic microorganism as Solutions, creams, gels, emulsions or mousses, or alterna defined previously as first cosmetic active agent or, as tively in the form of aerosol compositions also containing a also previously defined, as third or additional cosmetic propellant under pressure. active agent. In particular, a probiotic microorganism 0300. A topical composition according to the invention, that is Suitable for use as antidandruff active agent may especially a second composition, may advantageously befor be a microorganism chosen from Lactobacillus para mulated in any galenical form that is suitable for haircare, casei, Bifidobacterium longum and Vitreoscilla filifor especially in the form of a hair lotion, a shampoo, especially mis, especially formulated in the form of a lysate as an antidandruff shampoo, a hair conditioner, a detangler, a indicated hereinabove, hair cream or gel, a styling lacquer, a hairSetting lotion, a treating lotion, a dye composition (especially for oxidation 0285 and mixtures thereof. dyeing) optionally in the form of a colouring shampoo, a 0286 Preferentially examples of antidandruff agents that hair-restructuring lotion, a permanent-waving composition, a may especially be mentioned include Zinc pyridinethione, lotion or gel for combatinghair loss, an antiparasitic shampoo salicylic acid, selenium disulfide, mixed oil of thyme and of or a medicated shampoo, especially an anti-seborrhoea sham catnip, octopiroX or a probiotic microorganism, and mixtures poo, a scalp care product, which is especially anti-irritant, thereof. anti-ageing or restructuring, or which activates the blood 0287. By way of preferred examples of antidandruff circulation. agents, mention may in particular be made of Zinc pyrithione, 0301 When the composition of the invention is an emul salicylic acid and selenium disulphide, and mixtures thereof. Sion, the proportion of the fatty phase may range from 5% to 0288 A composition according to the invention advanta 80% by weight, and preferably from 10% to 50% by weight, geously comprises from 0.001% to 10% by weight, prefer relative to the total weight of the composition. The oils, the ably from 0.1% to 5% by weight and even more preferentially emulsifiers and the coemulsifiers used in the composition in emulsion form are chosen from those conventionally used in from 0.2% to 2% by weight of antidandruff agent(s) relative the cosmetics and/or dermatological field. The emulsifier and to the total weight of the composition. the coemulsifier may be present, in the composition, in a 0289 Compositions and Assembly proportion ranging from 0.3% to 30% by weight, and prefer 0290 An assembly in accordance with the invention com ably from 0.5% to 20% by weight, relative to the total weight prises at least a first and a second cosmetic compositions, the of the composition. first composition comprising at least an effective amount of at 0302) When the composition of the invention is an oily gel least a first cosmetic active agent, the said first cosmetic active or solution, the fatty phase may represent more than 90% of agent being Lactobacillus paracasei, a fraction thereofand/or the total weight of the composition. a metabolite thereof, and the second composition comprising 0303. In a known manner, the galenic forms for topical at least an effective amount of at least a second cosmetic administration may also contain adjuvants that are customary active agent chosen from antidandruffactive agents and being in the cosmetics, pharmaceutical and/or dermatological field, administered topically. Such as hydrophilic or lipophilic gelling agents, hydrophilic 0291. According to one embodiment, an assembly in or lipophilic active agents, preservatives, antioxidants, Sol accordance with the invention may also comprise at least a vents, fragrances, fillers, Screens, odour absorbers and dye third composition comprising at least an effective amount of stuffs. The amounts of these various adjuvants are those con at least a third cosmetic active agent, especially as defined ventionally used in the field under consideration, and are, for previously. example, from 0.01% to 20% of the total weight of the com 0292 Such a third composition may be administered position. Depending on their nature, these adjuvants may be orally or topically. introduced into the fatty phase and/or into the aqueous phase. US 2011/0014248 A1 Jan. 20, 2011 13

0304. As fatty substances that may be used in the inven Supplement or enriched food, for example food bars or com tion, mention may be made of mineral oils such as, for pacted or non-compacted powders. The powders may be example, hydrogenated polyisobutene and liquid petroleum diluted in water, soda, milk products or soya bean derivatives, jelly, plant oils such as, for example, a liquid fraction of shea or may be incorporated into food bars. butter, Sunflower oil and apricot kernel oil, animal oils such 0315. A microorganism of the invention, a fraction thereof as, for example, perhydrosqualene, synthetic oils, in particu and/or a metabolite thereof, may moreover be formulated lar Purcellin oil, isopropyl myristate and ethylhexyl palmi with the usual excipients and components for Such oral com tate, unsaturated fatty acids and fluoro oils such as, for positions or food Supplements, i.e. in particular fatty and/or example, perfluoropolyethers. Use may also be made offatty aqueous components, humectants, thickeners, preservatives, alcohols, fatty acids such as, for example, Stearic acid and texturing agents, flavour enhancers and/or coating agents, Such as, for example, waxes, in particular paraffin wax, car antioxidants, preservatives and dyes that are customary in the nauba wax and beeswax. Use may also be made of silicone food sector. compounds such as silicone oils and, for example, cyclom 0316 The formulating agents and excipients for oral com ethicone and dimethicone, and silicone waxes, resins and positions, and in particular for food Supplements, are known guns. in this field and will not be the subject of a detailed description 0305 As emulsifiers that may be used in the invention, herein. mention may, for example, be made of glyceryl Stearate, 0317 Milk, yogurt, cheese, fermented milks, milk-based polysorbate 60, the mixture of cetylstearyl alcohol/oxyethyl fermented products, ice creams, cereal-based products or fer enated cetylstearyl alcohol comprising 33 mol of ethylene mented cereal-based products, milk-based powders, infant oxide, sold under the name Sinnowax AOR by the company and baby formulas, food products of confectionary, chocolate Henkel, the mixture of PEG-6/PEG-32/glycol stearate sold or cereal type, animal feed, in particular for domestic animals, under the name Tefose(R) 63 by the company Gattefosse, tablets, gel capsules or lozenges, liquid bacterial Suspensions, PPG-3 myristylether, silicone emulsifiers such as cetyl dime oral Supplements in dry form and oral Supplements in liquid thicone copolyol and Sorbitan monostearate or tristearate, form are especially Suitable for use as dietetic or pharmaceu PEG-40 stearate, or oxyethylenated sorbitan monostearate tical Supports. (20 EO). 0318 According to one embodiment, a composition 0306 As solvents that may be used in the invention, men according to the invention administered orally, especially a tion may be made of lower alcohols, especially ethanol and first composition, may be formulated in the form of coated isopropanol, and propylene glycol. tablets, gel capsules, gels, emulsions, tablets, capsules, 0307 The composition of the invention may also advan hydrogels, food bars, compact or loose powders, liquid Sus tageously contain a spring and/or mineral water, in particular pensions or solutions, confectionery products, fermented chosen from Vittel water, waters from the Vichy basin, and la milks, fermented cheeses, chewing gum, toothpaste or spray Roche Posay water. Solutions or food carriers. 0308 As hydrophilic gelling agents, mention may be 0319. In the description and in the examples that follow, made of carboxylic polymers such as carbomer, acrylic unless otherwise indicated, the percentages are percentages copolymers such as acrylate/alkyl acrylate copolymers, poly by weight and the ranges of values written in the form acrylamides, and in particular the mixture of polyacrylamide, “between . . . and . . . include the upper and lower limits C13-14 isoparaffin and Laureth-7 sold under the name Sepi specified. gel 305(R) by the company SEPPIC, polysaccharides, for 0320. The ingredients are mixed, before being formulated, instance derivatives such as hydroxyalkylcelluloses, and in in the order and under conditions that can be readily deter particular hydroxypropylcellulose and hydroxyethylcellu mined by those skilled in the art. lose, natural gums such as guar gum, locust bean gum, carob 0321. The content and the nature of the ingredients used in and Xanthan gum, and clays. the compositions of the invention are adjusted by those 0309 As lipophilic gelling agents, mention may be made skilled in the artin such away as not to substantially affect the of modified clays such as bentones, metal salts of fatty acids, properties required for the compositions of the invention. Such as aluminium Stearates and hydrophobic silica, or else ethylcellulose and polyethylene. EXAMPLES 0310. In the case of oral use in accordance with the inven tion for oral administration, the use of an ingestible Support or Example 1 carrier is preferred. 0311. The ingestible support or carrier may be of diverse Powder Stick nature depending on the type of composition under consider ation. 0322 0312 Tablets or lozenges, oral supplements in dry form and oral Supplements in liquid form are thus in particular Suitable for use as dietetic orpharmaceutical Supports or food Active ingredient carriers. Lactobacilius paracasei ST11 100 cfu 0313 They may be, for example, food supplements, the Excipient formulation of which may be formulated via the usual pro cesses for in particular producing Sugar-coated tablets, gel Xanthan gum 0.8 mg capsules, gels, emulsions, tablets, capsules and hydrogels Sodium benzoate 0.2 mg allowing controlled release. Maltodextrin qs 30 g 0314. In particular, a microorganism according to the invention may be incorporated into any other form of food 0323. One stick per day may be taken. US 2011/0014248 A1 Jan. 20, 2011

Example 2 0329. This type of sugar-coated tablet can be taken 1 to 3 Powder Stick times a day. 0324 Example 5 0330 Active ingredient Lactobacilius paracasei ST11 109 cfu Excipient Scalp lotion Xanthan gum 0.8 mg Sodium benzoate 0.2 mg % by weight Maltodextrin qs 30 g Lactobacilius paracasei ST11 powder S.OO 0325 One stick per day may be taken. Lactobacilius johnsonii powder S.OO Antioxidant O.OS Example 3 Isopropanol 40.O Preservative O.30 Formulation of Sugar-Coated Tablet Type Water qs 100 0326 Example 6 Active materials mg/Sugar Lactobacilius paracasei ST11 5 x 10cfu 0331 Excipient of the Sugar-coated Microcrystalline cellulose 70 Encompress TM 60 Scalp care milk Magnesium Stearate 3 Anhydrous colloidal silica 1 % by weight Coating agent Lactobacilius paracasei ST11 powder S.OO Shellac 5 Glyceryl Stearate 1.00 Talc 61 Oil of cetylstearyl alcohol/oxyethylenated Saccharose 250 cetylstearyl alcohol Polyvidone 6 comprising 30 mol EO (Sinnowax AO (R) sold 3.00 Titanium dioxide O.3 by the company Henkel) Colouring agent 5 Cetyl alcohol 1.00 Dimethicone (DC 200 Fluid (R) sold by the 1.00 company Dow Corning) Liquid petroleum jelly 6.OO 0327. This type of sugar-coated tablet can be taken 1 to 3 Isopropyl myristate (Estol IMP 1514 (R) 3.00 times a day. sold by Unichema) Antioxidant O.OS Example 4 Glycerol 2O.OO Preservative O.30 Formulation of Sugar-Coated Tablet Type Water qs 100 0328 Example 7 Active materials mg/Sugar 0332 Lactobacilius paracasei ST11 10 cfu Lactobacilius johnsonii 10 cfu Excipient of the Sugar-coated Microcrystalline cellulose 70 Scalp care gel Encompress TM 60 % by weight Magnesium Stearate 3 Anhydrous colloidal silica 1 Lactobacillus paracasei ST11 powder S.OO Coating agent Hydroxypropylcellulose (Klucel H (R) sold by the company S.OO Hercules) 1.OO Shellac 5 Vitamin E 2.50 Talc 61 Antioxidant O.OS Saccharose 250 Isopropanol 40.OO Polyvinylidone 6 Preservative O.30 Titanium dioxide O.3 Water qs 100 Colouring agent 5 US 2011/0014248 A1 Jan. 20, 2011 15

Example 8 dandruff condition and seborrhoeic dermatitis of the scalp. from the viewpoint of a placebo composition (A). The com 0333 positions are of the following formulation: 0338 A: Maltodextrin 0339 B: 1x10 cfu/g Lactobacillus paracasei ST11 NCC Scalp care milk 2461 (CNCM I-2116). 0340. The treatment comprises daily oral administration % by weight ofa single amount of treatment for a period of eight weeks (56 Lactobacilius paracasei ST11 powder S.OO days). Glyceryl Stearate 1.OO 0341 This study was carried out on 66 adult male indi Cetylstearyl alcohol/oxyethylenated cetylstearyl 3.00 viduals between 18 and 60 years old, and who were identified alcohol comprising 3 mol EO (Sinnowax AO (R) sold by the company Henkel) subsequent to a clinical evaluation of their dandruff condi Cetyl alcohol 1.OO tion, classified from moderate to severe, with scores greater Dimethicone (DC 200 Fluid (R) sold by the company 1.OO than or equal to 3 (on a scale of 0 to 4) in the presence of Dow Corning) adherent scales on at least two quarters of the head. Liquid petroleum jelly 6.OO Isopropyl myristate (Estol IPM 1514 (R) sold by 3.00 0342. In the clinical evaluation, the presence of erythema the company Unichema) and of seborrhoeic dermatitis of the scalp were also taken into Glycerol 2O.OO consideration. Preservative O.30 0343. The 66 individuals were divided up into two parallel Water qs 100 groups of 33 individuals, with one group receiving the tested product and one group receiving the placebo. 0344) The effect of the supplement tested is assessed by Example 9 comparison with the placebo formulation at D1, D15, D29, D43, D57 and D64 (after the treatment had been interrupted 0334 for one week), through clinical evaluations and self-evalua tions carried out according to the following parameters: loose dandruff, adherent scales, erythema and seborrhoea of the Scalp, facial seborrhoea and pruritis. Scalp care cream 0345 The clinical parameters evaluated are the presence % by weight of loose and adherent dandruff, the presence of scales, Arachidyl behenyl alcohol arachidylglucoside 3.0 erythema, facial seborrhoea and seborrhoea of the scalp, and Isohexadecane 7.0 also measurement of the presence of Malassezia sp. yeast. Lactobacilius paracasei ST11 powder S.OO 0346. These evaluations are performed according to the Glycerol 2.0 usual techniques implemented in the field. Extract of Vitreoscilla filiformis 3.0 BHT O.OS 0347 The parameters self-evaluated by the individuals Methyl POB O.1 treated are the presence of dandruff, pruritis, the feeling of an Propyl POB O.OS oily condition, irritations, redness, the feeling of tautness and Water qs 100 the perception of the scalp, and also facial seborrhoea and seborrhoea of the hair. 0348. The results obtained show a noticeable improve Example 10 ment, from the first weeks of treatment onwards, in the dan druff condition, in the erythema and in the seborrhoeic der 0335) matitis of the scalp in the individuals treated with the composition B, compared with the individuals taking the placebo. 0349 These evaluations were completed by counting the Hair care gel yeast of the Malassezia sp. genus on the scalp. % by weight 0350 Results Lactobacilius paracasei ST11 powder S.OO 0351 A=Placebo (maltodextrin) Copper citrate 2.OO 0352 B-Lactobacillus paracasei, NCC 2461 (ST11) 10 Extract of Vitreoscilla filiformis 3.00 cfu/d Antioxidant O.OS Vitamin C 2.50 0353 1. Clinical Evaluation: Antioxidant O.OS 0354 a. Loose Dandruff Isopropanol 40.OO 0355 The results illustrated by FIG. 1 show a decrease in Preservative O.30 loose dandruff versus placebo, as a tendency from D15 (p=0. Water qs 100 057), significant at D29 and up to D57 (p<0.0001). 0356. The change between D1 and D57 is significant in favour of the active agent (p=0.0005). One week after inter Example 11 ruption of the treatment, at D64, the effectiveness is main Effectiveness Study tained versus placebo between D1 and D64 (p=0.0489). 0357 b. Adherent Dandruff 0336 Protocol 0358. The results illustrated by FIG. 2 show a significant 0337. An oral composition based on probiotic microor decrease in adherent dandruff versus placebo from D29 and ganism (B) was tested for its effectiveness with respect to the up to D57 (p<0.0001). US 2011/0014248 A1 Jan. 20, 2011

0359. The change between D1 and D57 is significant in 0373 This type of coated tablet may be taken 1 to 3 times favour of the active agent (p=0.0005). a day. 0360 c. Erythema 0361. The results illustrated by FIG. 3 show a significant Second Composition decrease in erythema versus placebo from D29 and up to D57 0374 (p=0.0015). 0362. The change between D1 and D57 is significant in favour of the active agent (p=0.00469). It is observed that the effectiveness of the composition of the invention is com Topical formulation pletely maintained between D57 and D64, from the viewpoint % by weight of this clinical aspect. Acrylates/C10-30 alkyl acrylate crosspolymer O.20% 0363. 2. Self-Evaluations: Propylene glycol 1.00% 0364 The results obtained by self-evaluation show pro Sodium laureth Sulfate (3 mol at 28%) 45.00 Dimethicone PEG-7 avocadoate O.30% files of the same type as those observed by clinical evaluation Zinc pyridinethione O.40% for the various parameters studied. Triisopropanolamine O.25% 0365. In particular, the effectiveness of the active agent Deionized water qs 100% with respect to pruritis is observed with a significant effect between D1 and D57 versus placebo (p=0.0427). 0366 Likewise, the volunteers judged the decrease in the Example 13 oily condition of their scalp to be very Substantial and signifi cant between D1 and D57 versus placebo (p=0.0300). For the First Composition facial seborrhoea, a tendency at D57 versus placebo is 0375 observed in favour of the probiotic, with a decrease in sebor rhoea (p=0.1735). 0367 3. Malassezia sp.: 0368. The results illustrated by FIG. 4 show a significant Scalp lotion decrease in Malassezia sp. for the product versus placebo % by weight from D15 (p=0.0237). Lactobacilius paracasei ST11 powder S.OO 0369. The change between D1 and D57 is significant for Antioxidant O.OS the active agent (p=0.0272) whereas there is no variation Isopropanol 40.O Preserving agent O.30 between D1 and D57 for the placebo. Water qs 100% 0370. One week after the treatment, at D64, the effective ness of the product is maintained (tendency towards effect versus placebo, p=0.2312). 0371. The following examples are examples of composi Second Composition tions useful for a process or an assembly in accordance with 0376 the invention.

Example 12 Antidandruff shampoo First Composition % by weight Acrylates/C10-30 alkyl acrylate crosspolymer O.20% 0372 Formulation of Coated Tablet Type Propylene glycol 1.00% Sodium laureth Sulfate (3 mol at 28%) 45.00 Dimethicone PEG-7 avocadoate O.30% Zinc pyridinethione O.40% Triisopropanolamine O.25% Active material mg/coated Deionized water qs 100% Lactobacilius paracasei ST11 10 cfu Lactobacilius johnsonii 10 cfu Excipient for the core of the Example 14 Microcrystalline cellulose 70 Encompress TM 60 First Composition Magnesium Stearate 3 Anhydrous colloidal silica 1 0377 Coating agent

Shellac 5 Talc 61 Scalp care cream Sucrose 250 Polyvinylpyrrollidone 6 % by weight Titanium dioxide O.3 Colorant 5 Arachidyl behenyl alcohol arachidylglucoside 3.0% Isohexadecane 7.0% US 2011/0014248 A1 Jan. 20, 2011 17

Example 16 -continued Efficacy Study Scalp care cream 0381 Protocol % by weight 0382 An assembly comprising a first oral composition Lactobacilius paracasei ST11 powder S.00% based on probiotic microorganism (A) and a second topical Glycerol 2.0% composition based on Zinc pyridinethione (B) was tested as Vitreoscilla filiformis extract 3.0 regards its efficacy towards scalp dandruff relative to the BHT O.OS administration of compositions (A) and (B) alone. The com Methyl POB O.1 Propyl POB O.OS positions have the following formulation: Water qs 100% (0383 A: 1x10 cfu/g of Lactobacillus paracasei ST11 NCC 2461 (CNCM I-2116) 0384 B: shampoo containing 1% zinc pyridinethione 0385. The treatment consists in administering daily via the Second Composition oral route composition (A) as a single dose and via the topical 0378 route composition (B), over four weeks, and then composi tion (A) alone over a further four weeks. For comparative purposes, composition (A) is administered alone orally or composition (B) is administered alone topically over eight Antidandrufflotion weeks. % by weight 0386 This study was performed on 99 male adults aged between 18 and 60, who were identified following a clinical Acrylates/C10-30 alkyl acrylate crosspolymer O.20% Propylene glycol 1.00% evaluation of their dandruff condition, classified from mod Ethanol 60% erate to severe, with scores of greater than or equal to 3 (on a Dimethicone PEG-7 avocadoate O.30% scale from 0 to 4) in the presence of squamae adhering to at Octopirox 1.00% least two quarters of the head, and of their scalp erythema. Triisopropanolamine O.25% 0387. In the clinical evaluation, the presence of erythema Deionized water qs 100% was also taken into account. 0388. The 99 individuals were divided into three parallel groups of 33 individuals, with one group receiving composi Example 15 tions (A) and (B) and then composition (A) alone, one group First Composition receiving composition (A) alone and one group receiving composition (B) alone. 0379 0389. The effects of an assembly and of a process of the invention were tested and assessed by comparison of the three groups on D1, D15, D29, D43 and D57 by means of clinical evaluations performed on the following parameters: free dan Scalp treating lotion druff, adherent squamae and erythema, and the overall score % by weight was calculated. 0390 These evaluations were performed by qualified der Bifidobacterium longum lysate 5.00** Magnesium gluconate 3.00 matologists according to the techniques usually used in the Calcium lactate 2.00 field. Antioxidant O.OS 0391 Clinical Evaluation of the Scalp Dandruff (Scores) Isopropanol 40.O 0392 At each visit, the dandruff condition, free dandruff Preserving agent O.30 and adherent Squamae, was scored, for each item, by the investigator using a scale from 0 to 4 on each of the head quarters as follows: Second Composition 0393 0 absent 0394) 1 very mild 0380 0395. 2 mild 0396 3 moderate 0397 4 severe Antidandruff shampoo 0398. The sum of the scores for the head quarters as regards the free dandruff and the adherent Squamae was cal % by weight culated (and thus the scores for each of the two items could be Acrylates/C10-30 alkyl acrylate crosspolymer O.20% between 0 and 16). Propylene glycol 1.00% 0399 Clinical Evaluation of the Scalp Erythema Sodium Laureth Sulfate (3 mol at 28%) 4S.OO Dimethicone PEG-7 avocadoate O.30% 0400. At each visit, the scalp erythema was scored by the Mixed oil of thyme and catnip 1.00% investigator using a scale from 0 to 4 on each of the head Zinc pyridinethione 20% quarters as follows: Triisopropanolamine O.25% Deionized water qs 100% 04.01 0 absent 04.02 1 very mild 0403. 2 mild US 2011/0014248 A1 Jan. 20, 2011

0404 3 moderate bacterium bifidum, Bifidobacterium breve, Bifidobacterium 04.05 4 severe longum, Bifidobacterium animalis, Bifidobacterium lactis, 0406. The sum of the scores for the head quarters was Bifidobacterium infantis, Bifidobacterium adolescentis and calculated (and thus the scores could be between 0 and 16). Bifidobacterium pseudocatenulatum. 0407 Overall Clinical Score (Dandruff/Erythema Scores) 8. The method according to claim 7, wherein the microor 0408. The overall clinical score is calculated by adding the ganism comprises Lactobacillus paracasei. scores for the free dandruff, adherent squamae and erythema. 9. The method according to claim 1, wherein the microor 04.09. The scores may be between 0 and 48. Thus, scores ganism is administered in a composition comprising the running from 13 to 9 are clinically advantageous, since a microorganism in an amount of from 0.0001% to 20% by score of 9 corresponds to the score generally found in dan weight relative to a total weight of the composition. druff-free individuals (score of 3 for each of the items). 10. The method according to claim 1, wherein the micro 0410. Results organism is administered topically or orally. 0411. The results (expressed as a total clinical score 11. The method according to claim 1, wherein the micro (TCS), corresponding to the score for free dandruff and organism comprises: adherent dandruff and for the erythema, show a significant a first microorganism of the Lactobacillus genus; and improvement, from the first weeks of treatment, of the dan a second microorganism different from the first microor druff condition and the erythema of the scalp in the case of the ganism. individuals treated with the combination (A)+(B) and accord 12. The method according to claim 11, in which the second ing to the process of the invention, relative to the individuals microorganism comprises at least one microorganism of at receiving composition (A) or (B) alone. least one genus selected from the group consisting of Saccha 0412. In particular, the efficacy of the antidandruff treat romyces, Yarrowia, Kluyveromyces, Torulaspora, Schizosac ment is manifested from the very first days of treatment and charomyces pombe, Debaromyces, Candida, Pichia, lasts throughout the treatment with increased intensity, lead Aspergillus, Penicillium, Bifidobacterium, Bacteroides, ing to a markedly improved clinical score. Fusobacterium, MelissocOccus, Propionibacterium, Entero 0413. On the other hand, administration of the probiotic coccus, Lactococcus, Staphylococcus, Peptostrepococcus, alone is reflected by a clinical effect that is essentially mani Bacillus, Pediococcus, Micrococcus, Leuconostoc, Weissella, fested towards the final weeks of treatment, whereas the Aerococcus, Oenococcus and Lactobacillus. administration of the antidandruffactive agent alone exerts an 13. A method for preparing a pharmaceutical or dermato effect that is visible at the start of the treatment, but that ends logical composition for preventing and/or treating inflamma up by Vanishing quickly. tion of the scalp, comprising: 0414. Where a numerical limit or range is stated herein, combining an effective amount of at least one probiotic the endpoints are included. Also, all values and Subranges microorganism and/or a fraction thereof with of least within a numerical limit or range are specifically included as one pharmaceutical or dermatological excipient. if explicitly written out. 0415. Obviously, numerous modifications and variations 14. A cosmetic and/or dermatological composition, that is of the present invention are possible in light of the above ofuse for preventing and/or treating scalp disorders, compris teachings. It is therefore to be understood that, within the ing, in a physiologically acceptable medium: Scope of the appended claims, the invention may be practiced an effective amount of at least one probiotic microorgan otherwise than as specifically described herein. ism, a fraction thereof and/or a metabolite thereof, and 0416 All patents and other references mentioned above an effective amount of at least one active agent selected are incorporated in full herein by this reference, the same as if from an antidandruff active agents and hydrating active set forth at length. agents. 1. A cosmetic method for preventing and/or treating a scalp 15. A cosmetic method for treating and/or preventing aes disorder, comprising: thetic disorders of the scalp in an individual, comprising: administering an effective amount of at least one probiotic administering an effective amount of at least one probiotic microorganism, a fraction thereof and/or a metabolite microorganism, a fraction thereof and/or a metabolite thereof to a subject in need of such prevention or treat thereof to the individual. ment. 16. A cosmetic process for preventing and/or treating a 2. The method according to claim 1, wherein the scalp dandruff condition of the scalp, comprising: disorder comprises a dandruff condition of the scalp. administering an effective amount of at least a first cos 3. The method according to claim 1, wherein the scalp metic active agent over a sequence of first and second disorder comprises discomfort of the scalp. consecutive periods of time to a subject in need of such 4. The method according to claim 1, wherein the scalp prevention and/or treatment; and disorder comprises unbalanced ecoflora of the scalp. administering at least a second cosmetic active agent, topi 5. The method according to claim 1, wherein the scalp cally, over one of the first and the second periods of time disorder comprises compromised integrity of the barrier to the subject; functions of the skin of the scalp. wherein: 6. The method according to claim 1, wherein the scalp the said first and second cosmetic active agents are formu disorder comprises pruritis and/or seborrhoeic dermatitis of lated in separate compositions; the scalp. the first cosmetic active agent comprises at least one pro 7. The method according to claim 1, wherein the microor biotic microorganism, a fraction thereof and/or a ganism comprises at least one member selected from the metabolite thereof, and group consisting of Lactobacillus johnsonii, Lactobacillus the second cosmetic active agent comprises at least one reuteri, Lactobacillus paracasei, Lactobacillus casei, Bifido antidandruff active agent. US 2011/0014248 A1 Jan. 20, 2011

17. The process according to claim 16, wherein the first Seborrhoea agent, an antibiotic, a hormone, an antian cosmetic active agent is administered orally or topically. drogen, an additional probiotic microorganism, a 18. The process according to claim 16, wherein the second hydrating agent, an antioxidant and a vitamin. cosmetic active agent is administered over the first period of 30. The process according to claim 29, wherein the third cosmetic active agent is formulated with the first and/or the time. second cosmetic active agent(s) and/or in a separate compo 19. The process according to claim 16, wherein the sition. sequence is repeated at least once. 31. A cosmetic assembly, comprising: 20. The process according to claim 16, wherein the first and at least a first and a second cosmetic composition; second periods of time range, independently of each other, wherein: from one to six weeks. 21. The process according to claim 16, wherein the dan the first composition comprises at least an effective amount druff condition of the scalp comprises dandruff in combina of at least a first cosmetic active agent comprising Lac tion with dryness of the scalp, hyperseborrhoea of the scalp. tobacillus paracasei, a fraction thereofand/or a metabo an imbalanced ecoflora, pruritus, inflammation of the scalp. lite thereof; or an imbalanced barrier function of the scalp. the second composition comprises at least an effective 22. The process according to claim 16, wherein the first amount of at least a second cosmetic active agent cosmetic active agent comprises at least one member selected Selected from antidandruff active agents for topical from the group consisting of Lactobacillus sp., Bifidobacte administration. rium sp., Cocci, yeasts and sporulated bacteria. 32. The assembly according to claim 31, wherein the sec 23. The process according to claim 16, wherein the first ond cosmetic active agent comprises at least one member cosmetic active agent comprises at least one member selected selected from the group consisting of pyridinethione salts, from the group consisting of Lactobacillus sp., Sporolacto trihalocarbamides of formula: bacillus sp., Enterococcus sp., Lactococcus sp., Bacillus sp., Streptococcus sp., Pediococcus sp., Leuconostoc sp. and Bifi dobacterium sp. Z NHCONH 24. The process according to claim 16, wherein the first cosmetic active agent comprises Lactobacillus paracasei. 25. The process according to claim 16, wherein the first C C cosmetic active agent is administered as a composition com prising the first cosmetic active agent in an amount of from in which Z represents a halogen atom or a C-C trihaloalkyl 0.0001% to 20% by weight relative to a total weight of the group Such as CF, triclosan, azole compounds, antifungal composition. polymers, selenium sulfides, Sulfur in its various forms, allan 26. The process according to claim 16, wherein the second toin, coal or wood tars and derivatives thereof, salicylic acid, cosmetic active agent comprises at least one member selected undecylenic acid, fumaric acid, allylamines and mixtures from the group consisting of pyridinethione salts, trihalocar thereof. ciclopirox, octopirox, piroctone olamine, clobetasol bamides of formula: propionate, betamethasone Valerate, tea tree oil, mixed oil of thyme and catnip, and a probiotic microorganism. 33. The assembly according to claim 31, wherein the first Z NHCONH composition is formulated in the form of coated tablets, gel capsules, gels, emulsions, tablets, capsules, hydrogels, food bars, loose or compact powders, liquid Suspensions or solu C C tions, confectionery products, fermented milks, fermented cheeses, chewing gum, toothpaste or spray solutions. 34. The assembly according to claim 31, wherein the sec in which Z represents a halogenatom or a C-C trihaloalkyl ond composition comprises at least one member selected group Such as CF, triclosan, azole compounds, antifungal from the group consisting of a hair lotion, a shampoo, a hair polymers, selenium sulfides, Sulfur in its various forms, allan conditioner, a detangler, a hair cream or gel, a styling lacquer, toin, coal or wood tars and derivatives thereof. Salicylic acid, a hairSetting lotion, a treating lotion, a dye composition, a undecylenic acid, fumaric acid, allylamines and mixtures hair-restructuring lotion, a permanent-waving composition, a thereof. ciclopirox, octopirox, piroctone olamine, clobetasol lotion or gel for combatinghair loss, an antiparasitic shampoo propionate, betamethasone Valerate, tea tree oil, mixed oil of or a medicated shampoo, and a scalp care product. thyme and catnip, and a probiotic microorganism. 35. The assembly according to claim 31, further compris 27. The process according to claim 16, wherein the second ing at least a third composition comprising at least an effec cosmetic active agent comprises at least one member selected tive amount of at least a third cosmetic active agent. from the group consisting of Zinc pyridinethione, salicylic 36. A cosmetic method for preventing and/or treating a acid, selenium disulfide, mixed oil of thyme and catnip, dandruff condition of the scalp, comprising: octopiroX and a probiotic microorganism. administering at least an effective amount of at least a first 28. The process according to claim 16, wherein the second and a second cosmetic active agent to a Subject in need of active agent is administered as a composition comprising the Such prevention or treatment; second cosmetic active agent in an amount of from 0.001% to wherein: 10% by weight relative to a total weight of the composition. the first cosmetic active agent comprises Lactobacillus 29. The process according to claim 16, further comprising: paracasei, a fraction thereof and/or a metabolite thereof. administering at least one third cosmetic active agent and Selected from the group consisting of a hair dyeing the second active agent is selected from antidandruffactive agent, an agent for preventing hair loss and/or for pro agents for topical administration. moting hair regrowth, a detangler, a hair shaping agent, an agent for preventing and/or treating baldness, an anti c c c c c